---
figid: PMC7017752__nihms-1065758-f0003
figlink: pmc/articles/PMC7017752/figure/F3/
number: Figure 3
caption: Plexiform neurofibromas (PNFs) develop from NF1+/− Schwann cells (SC) with
  a second hit resulting in NF1 biallelic inactivation (NF1−/−). These tumors comprise
  a mixture of SCs, mast cells, macrophages and fibroblasts intrinsic to the peripheral
  nerve. The growth of PNFs depends on the complex interplay between these cell types.
  KIT ligand is secreted by NF1−/− SCs and acts as a chemo-attractant for NF1+/− mast
  cells. In turn, NF1+/− mast cells produce TGFβ, stimulating NF1+/− fibroblasts to
  increase collagen production and other extracellular matrix (ECM) proteins. NF1+/−
  mast cells also produce heparin, vascular endothelial growth factor (VEGF) and matrix
  metalloproteinases (MMPs) promoting tumor vascularization and tumor invasiveness.
  NF1−/− SCs secrete colony-stimulating factor (CSF1) thereby recruiting macrophages,
  aiding tumor progression. Small molecule inhibitors in NF1 clinical trials are shown
  in red. Recent reports have highlighted the importance of inflammation, increased
  signaling through the WNT/β-catenin pathway and misregulated miRNAs in PNFs, all
  of which may represent potential therapeutic targets.
pmcid: PMC7017752
papertitle: Emerging therapeutic targets for neurofibromatosis type 1 (NF1).
reftext: James A. Walker, et al. Expert Opin Ther Targets. ;22(5):419-437.
pmc_ranked_result_index: '95249'
pathway_score: 0.9269298
filename: nihms-1065758-f0003.jpg
figtitle: Emerging therapeutic targets for neurofibromatosis type 1 (NF1)
year: ''
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7017752__nihms-1065758-f0003.html
  '@type': Dataset
  description: Plexiform neurofibromas (PNFs) develop from NF1+/− Schwann cells (SC)
    with a second hit resulting in NF1 biallelic inactivation (NF1−/−). These tumors
    comprise a mixture of SCs, mast cells, macrophages and fibroblasts intrinsic to
    the peripheral nerve. The growth of PNFs depends on the complex interplay between
    these cell types. KIT ligand is secreted by NF1−/− SCs and acts as a chemo-attractant
    for NF1+/− mast cells. In turn, NF1+/− mast cells produce TGFβ, stimulating NF1+/−
    fibroblasts to increase collagen production and other extracellular matrix (ECM)
    proteins. NF1+/− mast cells also produce heparin, vascular endothelial growth
    factor (VEGF) and matrix metalloproteinases (MMPs) promoting tumor vascularization
    and tumor invasiveness. NF1−/− SCs secrete colony-stimulating factor (CSF1) thereby
    recruiting macrophages, aiding tumor progression. Small molecule inhibitors in
    NF1 clinical trials are shown in red. Recent reports have highlighted the importance
    of inflammation, increased signaling through the WNT/β-catenin pathway and misregulated
    miRNAs in PNFs, all of which may represent potential therapeutic targets.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PDGFRB
  - PDGFRA
  - NF1
  - FLT1
  - FLT4
  - KDR
  - VEGFD
  - VEGFB
  - PGF
  - VEGFA
  - VEGFC
  - KIT
  - CSF1
  - TGFB1
  - TGFB2
  - TGFB3
  - MMRN1
  - CTNNB1
  - WNT1
  - WNT5A
  - WNT6
  - WNT7A
  - WNT8A
  - WNT8B
  - WNT10B
  - WNT2B
  - WNT16
  - WNT2
  - WNT3
  - WNT7B
  - WNT11
  - WNT9A
  - WNT9B
  - WNT4
  - WNT10A
  - WNT5B
  - WNT3A
  - Sunitinib
  - Sorafenib
  - Imatinib
  - Cabozantinib
  - Cediranib
  - Pirfenidone
genes:
- word: PDGFR
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRB
  entrez: '5159'
- word: PDGFR
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRA
  entrez: '5156'
- word: NF1
  symbol: NF1
  source: hgnc_symbol
  hgnc_symbol: NF1
  entrez: '4763'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT1
  entrez: '2321'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT4
  entrez: '2324'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: KIT
  symbol: KIT
  source: hgnc_symbol
  hgnc_symbol: KIT
  entrez: '3815'
- word: NF1-
  symbol: NF1
  source: hgnc_symbol
  hgnc_symbol: NF1
  entrez: '4763'
- word: CSF1
  symbol: CSF1
  source: hgnc_symbol
  hgnc_symbol: CSF1
  entrez: '1435'
- word: TGFB
  symbol: TGFB
  source: bioentities_symbol
  hgnc_symbol: TGFB1
  entrez: '7040'
- word: TGFB
  symbol: TGFB
  source: bioentities_symbol
  hgnc_symbol: TGFB2
  entrez: '7042'
- word: TGFB
  symbol: TGFB
  source: bioentities_symbol
  hgnc_symbol: TGFB3
  entrez: '7043'
- word: ЕСМ
  symbol: ECM
  source: hgnc_alias_symbol
  hgnc_symbol: MMRN1
  entrez: '22915'
- word: NF1-
  symbol: NF1
  source: hgnc_symbol
  hgnc_symbol: NF1
  entrez: '4763'
- word: NF1-
  symbol: NF1
  source: hgnc_symbol
  hgnc_symbol: NF1
  entrez: '4763'
- word: 1WNT/Bcatenin
  symbol: BCATENIN
  source: bioentities_symbol
  hgnc_symbol: CTNNB1
  entrez: '1499'
- word: WNT/B
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT1
  entrez: '7471'
- word: WNT/B
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT5A
  entrez: '7474'
- word: WNT/B
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT6
  entrez: '7475'
- word: WNT/B
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT7A
  entrez: '7476'
- word: WNT/B
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT8A
  entrez: '7478'
- word: WNT/B
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT8B
  entrez: '7479'
- word: WNT/B
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT10B
  entrez: '7480'
- word: WNT/B
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT2B
  entrez: '7482'
- word: WNT/B
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT16
  entrez: '51384'
- word: WNT/B
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT2
  entrez: '7472'
- word: WNT/B
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT3
  entrez: '7473'
- word: WNT/B
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT7B
  entrez: '7477'
- word: WNT/B
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT11
  entrez: '7481'
- word: WNT/B
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT9A
  entrez: '7483'
- word: WNT/B
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT9B
  entrez: '7484'
- word: WNT/B
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT4
  entrez: '54361'
- word: WNT/B
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT10A
  entrez: '80326'
- word: WNT/B
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT5B
  entrez: '81029'
- word: WNT/B
  symbol: WNT
  source: bioentities_symbol
  hgnc_symbol: WNT3A
  entrez: '89780'
chemicals:
- word: Sunitinib
  source: MESH
  identifier: C473478
- word: Sorafenib
  source: MESH
  identifier: C471405
- word: Imatinib
  source: MESH
  identifier: C097613
- word: Cabozantinib
  source: MESH
  identifier: C558660
- word: Cediranib
  source: MESH
  identifier: C500926
- word: Pirfenidone
  source: MESH
  identifier: C093844
diseases: []
---
